Unlocking the Future of the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the market right now?
In recent times, there has been substantial growth in the market size of the vesicular monoamine transporter 2 (VMAT2) inhibitor. Projections show an increase from $1.13 billion in 2024 to $1.25 billion in 2025, translating to a compound annual growth rate (CAGR) of 10.6%. This substantial development in the historical period is due to factors such as the heightened occurrence of movement disorders, an escalating demand for efficacious treatment alternatives, increased awareness of tardive dyskinesia, a growing elderly population, and a rising inclination towards oral formulations.
How fast Is the market expected to grow, and what’s its future value?
In the forthcoming years, the market for vesicular monoamine transporter 2 (VMAT2) inhibitors is anticipated to witness accelerated expansion, reaching $1.85 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. The spike during the projected period can be credited to a rise in neurodegenerative disease occurrence, an escalated interest in targeted treatments, an enhanced focus on individualized medicine, substantial investment in R&D, and heightened awareness of psychiatric and movement disorders. Key trends for the prediction period encompass breakthroughs in neurological studies, advancements in medication formulation, a shift towards individualized and precision medicine, the creation of next-gen VMAT2 inhibitors, and the incorporation of digital health tech solutions.
Get your market report here!
What key factors are fueling the growth of the market?
The surge in instances of Parkinson’s disease is anticipated to stimulate the vesicular monoamine transporter 2 (VMAT2) inhibitor market’s growth in the coming years. Parkinson’s disease is a progressive neurological disorder characterized by movement impairment due to the decline of dopamine-generating cells in the brain. The present growth in incidences of Parkinson’s disease is largely due to factors including an aging population, improved diagnosis, environmental elements like toxins, genetic factors, and heightened awareness about the ailment. VMAT2 inhibitors aid in managing the symptoms of Parkinson’s by regulating dopamine release and lessening tremors and dyskinesia. For example, in December 2022, the Parkinson’s Foundation, an American nonprofit organization, reported that nearly 90,000 individuals were diagnosed with Parkinson’s disease in the U.S., indicating a 50% rise from the previous annual diagnosis estimate of 60,000. Consequently, the growing instances of Parkinson’s disease are propelling growth in the vesicular monoamine transporter 2 (VMAT2) inhibitor market.
What are the key segments defining the market?
The vesicular monoamine transporter 2 (VMAT2) inhibitor market covered in this report is segmented –
1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs
2) By Route Of Administration: Oral, Other Administrations
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment
2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders
3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders
4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp
Who are the key players steering the development of the market?
Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH
How are evolving market trends shaping Strategies?
Primary players in the vesicular monoamine transporter 2 (VMAT2) inhibitors marketplace are concentrating on the creation of innovative solutions like capsules, in an effort to augment patient adherence, boost drug stability, and maximize therapeutic effectiveness. Capsules, which are a form of solid medication encased in a gelatin or HPMC shield, support VMAT2 inhibitors by elevating drug stability, warranting accurate dosage, and increasing patient adherence. For example, Neurocrine Biosciences Inc., a biopharmaceutical organization based in the US, in July 2024, introduced Ingrezza Sprinkle (valbenazine) capsules. This new formulation of the VMAT2 inhibitor Ingrezza is designed to simplify administration for adults with tardive dyskinesia and chorea linked to Huntington’s disease who experience dysphagia or swallowing difficulties. Ingrezza Sprinkle provides the same efficient dosage options as Ingrezza and can be administered either by sprinkling the capsule’s contents onto soft food or by consuming the capsule in its entirety.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21317
Which regions are most influential in expanding the market?
North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Osteoporosis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report
Postmenopausal Osteoporosis Treatment Global Market Report 2025
Osteoporosis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
